Drugs in tuberculosis and leprosy

Meenakshi R. Ramanathan; Crystal K. Howell; James M. Sanders

doi:10.1016/bs.seda.2019.08.010

Drugs in tuberculosis and leprosy

Meenakshi R. Ramanathan, Crystal K. Howell, James M. Sanders

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Tuberculosis (TB) remains a global health threat with approximately 25% of the world's population infected with latent tuberculosis infection (LTBI). Approximately 10% of these patients will develop active TB. Both TB and leprosy are known for their infectious and contagious nature and with increasing resistance patterns emerging and treatment regimens requiring a combination of products (with variable toxicity profiles, drug–drug interactions, and treatment outcomes) to combat the resistance. In this chapter, we review the 2018 literature regarding the adverse effects of medications commonly used in TB and leprosy: aminoglycosides, bedaquiline, carbapenems, clofazimine, cycloserine, dapsone, ethambutol, fluoroquinolones, isoniazid, linezolid, macrolides, pyrazinamide, para-aminosalicylic acid, polypeptides, rifamycins, terizidone, and thiacetazone.

Original language	English
Title of host publication	Side Effects of Drugs Annual
Editors	Sidhartha D. Ray
Publisher	Elsevier B.V.
Pages	321-338
Number of pages	18
ISBN (Print)	9780128171639
DOIs	https://doi.org/10.1016/bs.seda.2019.08.010
State	Published - 2019

Publication series

Name	Side Effects of Drugs Annual
Volume	41
ISSN (Print)	0378-6080

Keywords

Adverse effects
Ethambutol
Isoniazid
Leprosy
Pyrazinamide
Rifamycins
Side effect
Tuberculosis

Access to Document

10.1016/bs.seda.2019.08.010

Link to publication in Scopus

Fingerprint Dive into the research topics of 'Drugs in tuberculosis and leprosy'. Together they form a unique fingerprint.

Cite this

@inbook{7459939b9b5143458efd772909ff289d,

title = "Drugs in tuberculosis and leprosy",

abstract = "Tuberculosis (TB) remains a global health threat with approximately 25% of the world's population infected with latent tuberculosis infection (LTBI). Approximately 10% of these patients will develop active TB. Both TB and leprosy are known for their infectious and contagious nature and with increasing resistance patterns emerging and treatment regimens requiring a combination of products (with variable toxicity profiles, drug–drug interactions, and treatment outcomes) to combat the resistance. In this chapter, we review the 2018 literature regarding the adverse effects of medications commonly used in TB and leprosy: aminoglycosides, bedaquiline, carbapenems, clofazimine, cycloserine, dapsone, ethambutol, fluoroquinolones, isoniazid, linezolid, macrolides, pyrazinamide, para-aminosalicylic acid, polypeptides, rifamycins, terizidone, and thiacetazone.",

keywords = "Adverse effects, Ethambutol, Isoniazid, Leprosy, Pyrazinamide, Rifamycins, Side effect, Tuberculosis",

author = "Ramanathan, {Meenakshi R.} and Howell, {Crystal K.} and Sanders, {James M.}",

year = "2019",

doi = "10.1016/bs.seda.2019.08.010",

language = "English",

isbn = "9780128171639",

series = "Side Effects of Drugs Annual",

publisher = "Elsevier B.V.",

pages = "321--338",

editor = "Ray, {Sidhartha D.}",

booktitle = "Side Effects of Drugs Annual",

}

TY - CHAP

T1 - Drugs in tuberculosis and leprosy

AU - Ramanathan, Meenakshi R.

AU - Howell, Crystal K.

AU - Sanders, James M.

PY - 2019

Y1 - 2019

N2 - Tuberculosis (TB) remains a global health threat with approximately 25% of the world's population infected with latent tuberculosis infection (LTBI). Approximately 10% of these patients will develop active TB. Both TB and leprosy are known for their infectious and contagious nature and with increasing resistance patterns emerging and treatment regimens requiring a combination of products (with variable toxicity profiles, drug–drug interactions, and treatment outcomes) to combat the resistance. In this chapter, we review the 2018 literature regarding the adverse effects of medications commonly used in TB and leprosy: aminoglycosides, bedaquiline, carbapenems, clofazimine, cycloserine, dapsone, ethambutol, fluoroquinolones, isoniazid, linezolid, macrolides, pyrazinamide, para-aminosalicylic acid, polypeptides, rifamycins, terizidone, and thiacetazone.

AB - Tuberculosis (TB) remains a global health threat with approximately 25% of the world's population infected with latent tuberculosis infection (LTBI). Approximately 10% of these patients will develop active TB. Both TB and leprosy are known for their infectious and contagious nature and with increasing resistance patterns emerging and treatment regimens requiring a combination of products (with variable toxicity profiles, drug–drug interactions, and treatment outcomes) to combat the resistance. In this chapter, we review the 2018 literature regarding the adverse effects of medications commonly used in TB and leprosy: aminoglycosides, bedaquiline, carbapenems, clofazimine, cycloserine, dapsone, ethambutol, fluoroquinolones, isoniazid, linezolid, macrolides, pyrazinamide, para-aminosalicylic acid, polypeptides, rifamycins, terizidone, and thiacetazone.

KW - Adverse effects

KW - Ethambutol

KW - Isoniazid

KW - Leprosy

KW - Pyrazinamide

KW - Rifamycins

KW - Side effect

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=85073527868&partnerID=8YFLogxK

U2 - 10.1016/bs.seda.2019.08.010

DO - 10.1016/bs.seda.2019.08.010

M3 - Chapter

AN - SCOPUS:85073527868

SN - 9780128171639

T3 - Side Effects of Drugs Annual

SP - 321

EP - 338

BT - Side Effects of Drugs Annual

A2 - Ray, Sidhartha D.

PB - Elsevier B.V.

ER -